Prediction of HER2 ‐Low Breast Cancer via Multimodal Ultrasound Imaging
Cancer Medicine · 2025
DOI: 10.1002/cam4.71156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Feihang Dai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Multimodal Imaging, Ultrasonography, Mammary. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postdoctoral Scientific Research Developmental Fund of Heilongjiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
Human epidermal growth factor receptor 2 (HER2) is a key biomarker for clinical management and prognostic evaluation of breast cancer patients. This study was aimed at assisting the preoperative and non‐invasive prediction of HER2‐low breast cancer using multimodal ultrasound imaging and clinicopathological indicators, providing valuable imaging information for clinical precision diagnosis and personalized treatment strategies, especially in the application of antibody‐drug conjugates such as T‐DXd. Materials and Methods This retrospective study included 147 pathologically confirmed breast cancer patients from two institutions: 101 in the training set and 46 in the external validation set. All patients underwent multimodal ultrasound (grayscale, color Doppler, elastography, and contrast‐enhanced imaging) and had complete clinicopathological data. Patients were categorized as HER2‐negative, HER2‐low, or HER2‐positive based on immunohistochemistry. Logistic regression was used to construct predictive models.
Results
Compared with the HER2‐negative group, low Ki‐67, PR positivity, longer rise time (RT), and lower Emax values were independent predictors of HER2‐low status ( p < 0.05), yielding an AUC of 0.876, sensitivity 0.833, and specificity 0.781. Compared with HER2‐positive cancers, HER2‐low cases showed low Ki‐67, ER/PR positivity, low Emax, and a DVPC pattern characterized by an initial increase followed by a subsequent decline as independent predictors ( p < 0.05), with an AUC of 0.929, sensitivity 0.905, and specificity 0.856. External validation confirmed robust model performance (AUC = 0.925 and 0.918 for HER2‐low vs. negative and positive, respectively).
Conclusion
A model integrating multimodal ultrasound and clinicopathological factors effectively predicts HER2‐low breast cancer, offering valuable imaging‐based support for clinical decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
- Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People's Republic of China.
ORCID-Profile: Feihang Dai, Tong Wu
Förderung
- Postdoctoral Scientific Research Developmental Fund of Heilongjiang Province
- National Natural Science Foundation of China
Zitieren
APA
Dai, F., Guo, B., Ai, X., Liu, D., Dai, L., Zhang, C., Leng, X., & Wu, T. (2025). Prediction of HER2 ‐Low Breast Cancer via Multimodal Ultrasound Imaging. Cancer Medicine. https://doi.org/10.1002/cam4.71156
Vancouver
Dai F, Guo B, Ai X, Liu D, Dai L, Zhang C, et al. Prediction of HER2 ‐Low Breast Cancer via Multimodal Ultrasound Imaging. Cancer Medicine. 2025. doi:10.1002/cam4.71156
BibTeX
@article{Dai2025,
author = {Dai, Feihang and Guo, Baoliang and Ai, Xin and Liu, Dandan and Dai, Longbin and Zhang, Chengzhi and Leng, Xiaoping and Wu, Tong},
title = {Prediction of HER2 ‐Low Breast Cancer via Multimodal Ultrasound Imaging},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71156}
}
EUVIMED